ID   RTFK-1
AC   CVCL_QZ53
DR   cancercelllines; CVCL_QZ53
DR   Wikidata; Q54951396
RX   PubMed=22490663;
CC   Population: Japanese.
CC   Selected for resistance to: ChEBI; CHEBI:175901; Gemcitabine (Gemzar).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Trp91Ter (c.272G>A); ClinVar=VCV000233650; Zygosity=Homozygous (from parent cell line).
CC   Misspelling: RTFKK-1; PubMed=22490663; Note=In supplementary figure 2.
CC   Derived from site: In situ; Extrahepatic bile duct; UBERON=UBERON_0003703.
DI   NCIt; C4436; Cholangiocarcinoma
DI   ORDO; Orphanet_70567; Cholangiocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_2214 ! TFK-1
SX   Male
AG   63Y
CA   Cancer cell line
DT   Created: 05-03-18; Last updated: 05-10-23; Version: 10
//
RX   PubMed=22490663; DOI=10.1016/j.bbrc.2012.03.122;
RA   Saiki Y., Yoshino Y., Fujimura H., Manabe T., Kudo Y., Shimada M.,
RA   Mano N., Nakano T., Lee Y., Shimizu S., Oba S., Fujiwara S.,
RA   Shimizu H., Chen N., Nezhad Z.K., Jin G., Fukushige S., Sunamura M.,
RA   Ishida M., Motoi F., Egawa S., Unno M., Horii A.;
RT   "DCK is frequently inactivated in acquired gemcitabine-resistant human
RT   cancer cells.";
RL   Biochem. Biophys. Res. Commun. 421:98-104(2012).
//